Open access peer-reviewed Edited Volume

Novel Topics in the Diagnosis, Treatment, and Follow-Up of Nephritis, Nephrotic Syndrome, and Nephrosis

Hulya Çiçek

Gaziantep University

Dr. Çiçek is currently a Professor at the Department of Medical Biochemistry/Gaziantep University School of Medicine. She is a member of editorial or reviewer boards of eminent international journals. She is an experienced manager in health institutions and laboratory management. She and her scientific team conduct research for the prevention, early detection, and treatment of cancer.


Mustafa Yıldırım

Sanko University

Necat Yilmaz

Antalya Training and Research Hospital

More Editors >
Mehmet Solakhan

Bahçeşehir University


Nephritis Diagnosis Treatment Pathology Nephrotic Syndrome Kidney Damage Diabetes Nephrosis Nephropathy Amyloid Nephrosis Osmotic Nephrosis Amyloid Light-Chain Amyloidosis

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Nephritis can be seen as hereditary or as a result of infection, immunological diseases, metabolic disorders, exposure to toxic factors, and glomerular or hematological diseases. It may be asymptomatic or accompanied by hypertension, renal tubular acidosis, proteinuria, hematuria, edema, anemia, glucosuria, and nocturia. It is a progressive and chronic disease with sometimes acute exacerbations. Chronic nephritis often leads to chronic kidney disease, causing tubular atrophy and interstitial fibrosis. It is seen in approximately 15% of the causes of end-stage kidney disease. Generally, the pathological findings are tubular atrophy and dilatation, fibrosis in the interstitial space, and inflammatory cell infiltration, mostly consisting of mononuclear cells. In the later stages of the disease, glomerulosclerosis and vascular sclerosis develop. Current treatment involves diagnosing and eliminating the causative factor of chronic interstitial nephritis and treating complications according to the extent of kidney damage, the treatment of chronic nephritis is difficult, and the prognosis is poor; treatment is aimed at the etiology. The search for antifibrotic treatment continues in experimental models; various hormones, immunosuppressants, and symptomatic treatments are given according to the degree of renal damage and complications. However, since these treatments are applied for a long time, they cause many complications in the patient.

Nephrotic syndrome is one of the most common chronic diseases of childhood in which many symptoms due to kidney damage are seen together. Massive proteinuria, hypoalbuminemia, hyperlipidemia, lipiduria, and edema are observed in the patient's clinic. 90% of childhood nephrotic syndrome cases are due to primary idiopathic or minimal change disease. It is often seen in adults due to focal segmental glomerulosclerosis, membranous nephropathy, lupus, or diabetes.
While histopathologically, the most common minimal change disease is focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, mesangial proliferation, proliferative glomerulonephritis, and membranous glomerulopathy can be seen. Treatment is planned according to symptoms, complications, and primary disease. The first goal is to minimize protein loss. Although corticosteroids are the first choice in treatment, if side effects occur or the disease does not respond, immunosuppressive treatments are applied. Current treatment approaches have shown promising results in terms of disease treatment. However, its long-term side effects and remission sustainability are still unclear.

Nephrosis is an inflammatory, neoplastic or non-vascular nephropathy that causes degenerative changes and solute accumulation in tubules and glomeruli. Nephrosis may be due to a primary cause or secondary to another disorder. Nephrosis is often seen as amyloid nephrosis and osmotic nephrosis. Osmotic nephrosis causes structural changes with intracytoplasmic vacuolization and swelling of tubular cells, occurring primarily in the proximal tubules, without a change in osmotic balance, resulting from certain solutes such as dextran, contrast dyes, mannitol, and hydroxyethyl starch. It can lead to clinical manifestations ranging from acute renal failure to chronic kidney disease.
Amyloid light-chain amyloidosis is the most common type of amyloidosis, with the kidney one of the organs most commonly affected. With the enlargement of the kidney area affected by amyloid deposits, proteinuria and renal dysfunction are usually observed. This topic includes advances in research on the etiology and pathogenesis of nephritis, nephrotic syndrome, and nephrosis, new early diagnosis methods, follow-up and treatment plans, and case series. It will provide significant opportunities and support to scientists, philosophic and medical doctors, urologists, nephrologists, public health practitioners, and family physicians from around the world to share new research, ideas, and solutions.

Publishing process

Book initiated and editor appointed

Date completed: May 12th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: June 9th 2022

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: August 8th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 27th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 26th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Hulya Çiçek

Gaziantep University

Dr. Çiçek received her medical degree from the Çukurova University School of Medicine in Adana/Turkey, in 1991. She completed her Biochemistry and Clinical Biochemistry residency training in 2004 at the Gaziantep University in Gaziantep, Turkey. She has graduated with a Master of Science in Management and Organization in social sciences. She was an Assistant Professor of Medical Biochemistry at Gaziantep University between 2007-and 2013. She became an Associate Professor in February 2013. She is currently a Professor at the Department of Medical Biochemistry/Gaziantep University School of Medicine since 2019. She also conducts academic studies in various disciplines. She worked as a thesis supervisor at the master's graduate and doctoral levels of many students. She is a member of editorial or reviewer boards of international eminent journals. Her research interests are focused on clinical biochemistry, biochemical technics, molecular biology, genetics, functional medicine, cancer research, nutrition, vitamin D, cardiac biomarkers, urology, neurologic diseases, dermatological biomarkers, obstetric and gynecology, and homocysteine. She is a member of The Turkish Society of Biochemistry, The Turkish Society of Clinical Biochemistry, and the Society of Clinical Biochemistry.

View profile

Book chapters authored 0

Books edited 0

Introducing your Author Service Manager

Mrs. Dajana Jusic

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in